{"gene":"BCL2A1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1995,"finding":"BFL-1 (BCL2A1) was identified as a novel BCL-2 family member with 72% amino acid identity to murine A1, containing conserved BH1 and BH2 domains, and preferentially expressed in bone marrow.","method":"cDNA cloning, sequence analysis, Northern blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — initial identification by sequence homology and expression analysis, replicated across multiple subsequent studies","pmids":["7478596"],"is_preprint":false},{"year":1996,"finding":"BFL-1 suppresses p53-induced apoptosis and cooperates with E1A oncogene in transformation of primary rodent epithelial cells, demonstrating anti-apoptotic and oncogenic activities.","method":"Overexpression in cell lines, apoptosis assay, transformation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assays with defined phenotypic readout, single lab, multiple orthogonal assays","pmids":["8752150"],"is_preprint":false},{"year":1998,"finding":"Mutational analysis of BFL-1 showed that BH1, BH2, and BH4 domains are required for anti-apoptotic, oncogene cooperation, and proliferation-facilitating activities, while BH3 mutation does not affect function. C-terminal 24 amino acid deletion partially reduces all activities. Gln residues in the N-terminal/BH4 region are essential for the proliferation-permitting activity.","method":"Site-directed mutagenesis, overexpression, apoptosis assays, transformation assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis across multiple domains with multiple orthogonal functional readouts in a single study","pmids":["9671389"],"is_preprint":false},{"year":2000,"finding":"BFL-1 interacts with BAX (but not BCL-2 or BCL-xL) via the BAX BH3 domain, as shown in yeast two-hybrid and co-immunoprecipitation. BFL-1 does not form homodimers. Overexpression confers resistance to apoptosis from serum deprivation in REF52 cells, and neutralizes BAX lethality in yeast. Molecular modeling suggests BFL-1 has a 7-alpha-helix core structure similar to BCL-xL.","method":"Yeast two-hybrid, co-immunoprecipitation, yeast lethality assay, molecular modeling, overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — yeast two-hybrid plus reciprocal co-IP, functional rescue assay, multiple orthogonal methods in one study","pmids":["10753914"],"is_preprint":false},{"year":2000,"finding":"EBV latent membrane protein LMP1 transcriptionally upregulates bfl-1 mRNA in Burkitt's lymphoma cells, partly through increased mRNA stability. Ectopic BFL-1 expression protects against apoptosis from growth factor deprivation in EBV-positive cells.","method":"Inducible LMP1 expression system, Northern blot, ectopic overexpression, apoptosis assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible system with defined pathway, single lab, multiple readouts","pmids":["10864681"],"is_preprint":false},{"year":2000,"finding":"TNF-alpha and chemotherapeutic agents upregulate BCL-xL and BFL-1/A1 expression via an NF-κB-dependent pathway in A549 lung cancer cells. Ectopic expression of BFL-1/A1 at physiological levels provides differential protection against TNF-alpha and chemotherapy in NF-κB-deficient cells.","method":"NF-κB inhibition, ectopic overexpression, cytotoxicity assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic NF-κB inhibition with overexpression rescue, single lab","pmids":["11039911"],"is_preprint":false},{"year":2003,"finding":"BCL2A1 encodes two HLA-restricted minor histocompatibility antigens (mHAgs) derived from SNP-encoded peptides, presented by HLA-A*2402 and HLA-B*4403 on hematopoietic lineage cells exclusively, identified by CTL clone lytic patterns and minigene transfection/epitope reconstitution assays.","method":"CTL clone lysis assays, minigene transfection, synthetic peptide epitope reconstitution, two-point linkage analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (CTL assays, minigene, peptide reconstitution) in one rigorous study","pmids":["12771180"],"is_preprint":false},{"year":2003,"finding":"A novel splice variant, Bfl-1S, contains four BH domains and a KKRK nuclear localization sequence at its C-terminus, which directs nuclear localization (demonstrated by GFP fusion confocal microscopy). Bfl-1S has anti-apoptotic function against Bax and staurosporine, inhibiting cleavage of Bid and caspases 3 and 8.","method":"RT-PCR, GFP fusion confocal microscopy, co-expression with Bax, caspase activity assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by imaging with functional validation, single lab","pmids":["12717423"],"is_preprint":false},{"year":2004,"finding":"LMP1 drives bfl-1 promoter activity via NF-κB-dependent mechanism involving TNFR-associated factor 2 recruitment, primarily through CTAR2 domain. A 95-bp promoter region with a novel NF-κB-like binding motif is essential for transactivation by LMP1, CD40, and NF-κB p65. CD40 activation similarly increases bfl-1 mRNA via NF-κB.","method":"Promoter-reporter assays, NF-κB inhibition, EMSA, deletion/mutation analysis of promoter","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter-reporter assays with deletion mapping, EMSA, multiple activating signals tested, single lab with multiple orthogonal methods","pmids":["14747545"],"is_preprint":false},{"year":2005,"finding":"Pre-TCR signaling induces BCL2A1 expression to promote pre-T cell survival by inhibiting caspase-3 activation. Knockdown of BCL2A1 compromises survival even in the presence of functional pre-TCR signaling.","method":"shRNA knockdown, caspase-3 activity assay, pre-TCR signaling pathway analysis","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown with defined cellular phenotype, pathway placement, single lab","pmids":["15728238"],"is_preprint":false},{"year":2005,"finding":"BCL2A1 is upregulated by Anaplasma phagocytophilum infection in neutrophils through transcriptional upregulation (blocked by actinomycin D), maintaining mitochondrial membrane potential and preventing caspase-3 activation to inhibit apoptosis.","method":"mRNA quantification, actinomycin D block, mitochondrial membrane potential dyes (Mitotracker/JC-1), caspase-3 activity assay","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods linking BCL2A1 transcription to mitochondrial and caspase outcomes, single lab","pmids":["15617521"],"is_preprint":false},{"year":2006,"finding":"BCL2A1 is a direct transcriptional target of WT1 (-Ex5/-KTS) isoform: promoter-reporter assays and chromatin immunoprecipitation showed direct WT1 binding and activation of the A1/BFL1 promoter. Constitutive A1 expression induces spontaneous granulocytic differentiation and resistance to apoptosis and chemotherapy in 32D cl3 myeloblasts.","method":"cDNA array, RT-PCR, promoter-reporter assay, chromatin immunoprecipitation, constitutive expression","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP plus promoter-reporter plus functional phenotype, multiple orthogonal methods in one study","pmids":["16484585"],"is_preprint":false},{"year":2006,"finding":"EBNA2 upregulates bfl-1 transcription through a CBF1/RBP-Jκ-dependent pathway (a Notch signaling component), requiring a core CBF1-binding site on the bfl-1 promoter, and acting independently of NF-κB. Loss of both EBNA2 and LMP1 together is required to significantly reduce bfl-1 expression.","method":"Promoter-reporter assays, CBF1 mutant analysis, EBV protein deletion, luciferase assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis with genetic epistasis, single lab","pmids":["16873269"],"is_preprint":false},{"year":2006,"finding":"ALK-positive ALCL cells require BCL2A1 expression for survival and growth; BCL2A1 is a transcriptional target of ALK signaling. Functional RNAi knockdown of BCL2A1 in ALK-positive ALCL cells suppresses transformation and survival.","method":"Gene expression profiling, inducible RNAi, ALK inhibitors, functional RNAi screen","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible RNAi with defined phenotypic readouts in multiple cell lines, single lab","pmids":["17111047"],"is_preprint":false},{"year":2007,"finding":"TNF-alpha induces BFL-1 expression in neutrophils at low concentrations (≤1 ng/mL) while at high concentrations (≥10 ng/mL) it triggers caspase-dependent Mcl-1 degradation. These opposing effects on two separate anti-apoptotic systems explain TNF-alpha's dual effects on neutrophil apoptosis.","method":"Western blot, flow cytometry, caspase inhibition, mRNA analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dose-dependent functional dissection with multiple readouts, single lab","pmids":["17942758"],"is_preprint":false},{"year":2007,"finding":"Spi-B transcription factor directly induces BCL2-A1 expression to control survival of plasmacytoid dendritic cells and their progenitors during differentiation from hematopoietic precursors.","method":"ChIP, promoter assay, siRNA knockdown, flow cytometry apoptosis assay, differentiation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP confirming direct binding plus knockdown plus functional outcome, multiple orthogonal methods","pmids":["22510878"],"is_preprint":false},{"year":2007,"finding":"The amphipathic tail-anchoring peptide (ATAP; residues 147-175) of Bfl-1 targets specifically to mitochondria and induces caspase-dependent apoptosis independent of Bax or Bak. Lysine residues flanking ATAP are required for mitochondrial targeting; charged residues contributing to amphipathic character are critical for pro-apoptotic function.","method":"GFP-fusion subcellular localization, mutagenesis, caspase assay, Bax/Bak-deficient cells","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis coupled with direct mitochondrial localization and functional apoptosis assays, multiple orthogonal methods","pmids":["17666431"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of BFL-1 in complex with a BIM BH3 peptide reveals distinct features at the peptide-binding site with local plasticity of hydrophobic interactions compared to MCL-1:BIM, suggesting the structural basis for multi-specificity of BIM binding to anti-apoptotic proteins.","method":"X-ray crystallography","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — first crystal structure of BFL-1, rigorous structural determination","pmids":["18812174"],"is_preprint":false},{"year":2008,"finding":"De novo synthesis of BCL2A1 (and BCL-xL) mediates ~1000-fold resistance to ABT-737 in CLL cells cultured on CD154-expressing fibroblasts with IL-4 (mimicking lymph node microenvironment), acting upstream of mitochondrial perturbation. BCL2A1 is responsible for resistance at high ABT-737 concentrations.","method":"Co-culture model, western blot, protein synthesis inhibition, flow cytometry apoptosis assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with upstream/downstream analysis, single lab, multiple methods","pmids":["19008458"],"is_preprint":false},{"year":2009,"finding":"The C-terminal helix α9 of Bfl-1 is amphipathic and required for mitochondrial membrane anchoring; endogenous Bfl-1 is tightly associated with mitochondria by its C-terminus in both healthy and apoptotic lymphocytes and malignant B cells. The amphipathic character of α9 regulates the anti-apoptotic function of Bfl-1, though it is not absolutely required for anti-apoptotic activity.","method":"Subcellular fractionation, confocal microscopy, molecular modeling, functional anti-apoptotic assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by fractionation and imaging with functional consequence, single lab","pmids":["19759007"],"is_preprint":false},{"year":2010,"finding":"Ubiquitination is a critical tumor suppressor mechanism for Bfl-1; ubiquitination-resistant mutants show increased protein stability and greatly accelerated tumor formation in a mouse leukemia/lymphoma model. Tyrosine kinase Lck is upregulated in these tumors and activates IκB kinase, Akt, and ERK signaling.","method":"Ubiquitination-resistant mutants, mouse leukemia/lymphoma model, shRNA knockdown, western blot","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo mouse model with ubiquitination-resistant mutants plus Lck knockdown rescue, multiple orthogonal methods","pmids":["20185581"],"is_preprint":false},{"year":2010,"finding":"Acquired resistance to ABT-737 in lymphoma cells is mediated by increased BFL-1 and/or MCL-1 proteins, which sequester pro-apoptotic BIM after it is displaced from BCL-2 by ABT-737. MCL-1 and BFL-1 upregulation occurs at the transcript level and is also dynamically induced within hours of ABT-737 treatment.","method":"Derived resistant cell lines, western blot, shRNA, BIM co-immunoprecipitation, flavopiridol treatment","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with co-IP and shRNA rescue, single lab","pmids":["20197552"],"is_preprint":false},{"year":2012,"finding":"µ-Calpain cleavage of full-length Bfl-1 releases C-terminal membrane-active α-helices, converting Bfl-1 from anti-apoptotic to pro-apoptotic. Helix α5 of Bfl-1 induces cell death and cytochrome c release through a Bax/Bak-dependent mechanism; helix α9 promotes cytochrome c release through a unique membrane-destabilizing action independent of Bax/Bak.","method":"In vitro calpain cleavage, isolated mitochondria permeabilization, Bax/Bak-deficient cells, cytochrome c release assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution with isolated mitochondria, domain mutagenesis, and Bax/Bak genetic controls","pmids":["22745672"],"is_preprint":false},{"year":2012,"finding":"HTLV-1 Tax protein induces bfl-1 transcription through the canonical NF-κB pathway, and cooperates with c-Jun or JunD (but not JunB) AP-1 transcription factors via NF-κB and AP-1 binding sites in the bfl-1 promoter. HBZ inhibits c-Jun-induced but increases JunD-induced bfl-1 activation. Both Bfl-1 and Bcl-xL (not Bcl-2) are required for HTLV-1-infected T-cell survival.","method":"Promoter-reporter assays, ChIP, siRNA knockdown, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP plus promoter-reporter mutation plus siRNA knockdown with survival readout, multiple orthogonal methods","pmids":["22553204"],"is_preprint":false},{"year":2013,"finding":"BCL2A1 is a direct transcriptional target of the melanoma oncogene MITF, which restricts high-level BCL2A1 expression to melanoma. BCL2A1 is recurrently amplified in ~30% of melanomas and is necessary for melanoma growth; BCL2A1 overexpression promotes melanomagenesis in BRAF-immortalized melanocytes.","method":"ChIP, promoter assays, shRNA knockdown, overexpression in melanocytes, in vivo xenograft","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP demonstrating direct MITF binding, functional knockdown and overexpression, in vivo model, multiple orthogonal methods","pmids":["23447565"],"is_preprint":false},{"year":2014,"finding":"Bfl-1 is mitochondrially resident in both resting and apoptotic melanocytes and is regulated by proteasome and NF-κB pathways. siRNA-mediated knockdown enhances sensitivity to drug treatments; forced Bfl-1 overexpression is protective against chemotherapy-induced apoptosis.","method":"Subcellular fractionation, siRNA knockdown, proteasome inhibition, NF-κB inhibition, overexpression, apoptosis assay","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence, multiple perturbations, single lab","pmids":["25486183"],"is_preprint":false},{"year":2015,"finding":"Conditional knockdown of BCL2A1/A1 in mice defines a critical role in mature B-cell homeostasis, and identifies the A1/Bim axis as a target of BCR-dependent survival signals mediated by Syk and Btk kinases.","method":"Conditional knockdown mouse model (rtTA-driven), flow cytometry, genetic epistasis with Syk/Btk inhibitors","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional in vivo knockdown with genetic pathway epistasis, multiple orthogonal experiments","pmids":["26450454"],"is_preprint":false},{"year":2016,"finding":"BFL-1 contains a unique surface-accessible cysteine (C55) within its BH3-binding groove. Stapled BH3 peptides bearing acrylamide warheads derived from NOXA BH3 form irreversible covalent bonds with C55 of BFL-1, selectively inhibiting BFL-1 and reactivating apoptosis. A natural juxtaposition of cysteines at the NOXA BH3/BFL-1 interface enables this selectivity.","method":"Covalent stapled peptide synthesis, mass spectrometry, in vitro binding assay, cell-based apoptosis assay","journal":"Cell chemical biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — structural rationale plus covalent chemistry validated by MS plus cell-based functional assay","pmids":["27617850"],"is_preprint":false},{"year":2016,"finding":"Human NOXA binds human BFL-1 potently and covalently via conserved Cys residues, with over 100-fold increased affinity over human MCL-1, suggesting that the selectivity of BH3 interactions differs between mouse and human sequences and that BFL-1 is the primary cellular target of NOXA in humans.","method":"Binding affinity measurements, mass spectrometry for covalent interaction, BH3 profiling","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding assays and covalent bond characterization by MS, single lab","pmids":["28026162"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of apo BFL-1 at 1.69-Å resolution reveals a surface-accessible C55 within the BH3-binding groove, unique among BCL-2 proteins. Crystal structure of BFL-1 in complex with a covalent stapled NOXA BH3 peptide shows sulfhydryl bond formation and a newly formed hydrophobic cavity with conformational change upon BH3 ligand binding.","method":"X-ray crystallography (apo and complex structures)","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — two crystal structures, rigorous structural determination with functional implications","pmids":["29276033"],"is_preprint":false},{"year":2017,"finding":"Computationally designed PUMA BH3 variants bearing epistatic mutations bind BFL-1 in a shifted geometry (revealed by crystal structure) with >150-fold selectivity for BFL-1 over other BCL-2 paralogs, potently trigger mitochondrial outer membrane permeabilization in BFL-1-dependent cells, and an electrophile-modified variant reacts with cysteine near the peptide-binding groove to augment specificity.","method":"Computational design, crystal structure, fluorescence polarization binding assay, mitochondrial permeabilization assay, cell-based selectivity assay","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus functional validation with mitochondrial assay and cellular selectivity, multiple orthogonal methods","pmids":["28594323"],"is_preprint":false},{"year":2018,"finding":"TRIM28 is an E3 ubiquitin ligase for BCL2A1; endogenous TRIM28 and BCL2A1 bind each other at mitochondria and TRIM28 knockdown decreases BCL2A1 ubiquitination. TRIM17 stabilizes BCL2A1 by blocking TRIM28 from binding and ubiquitinating BCL2A1. GSK3 is involved in phosphorylation-mediated inhibition of BCL2A1 degradation.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, subcellular fractionation, western blot","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP at mitochondria, knockdown demonstrating E3 activity, GSK3 pharmacological inhibition, multiple orthogonal methods","pmids":["30042493"],"is_preprint":false},{"year":2018,"finding":"MUC1-C activates the BCL2A1 gene via an NF-κB p65-mediated mechanism in TNBC cells, linking MUC1-C/NF-κB signaling to BCL2A1 induction and EMT. Genetic and pharmacologic targeting of MUC1-C suppresses BCL2A1 expression.","method":"shRNA and pharmacologic targeting of MUC1-C, NF-κB p65 ChIP/reporter assays, western blot","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacologic perturbations with NF-κB pathway evidence, single lab","pmids":["29760958"],"is_preprint":false},{"year":2018,"finding":"BFL1 inhibits apoptosis through three distinct membrane-level mechanisms (differing from BCLXL). Critically, changes in OMM lipid composition during apoptosis activate a pro-death function of BFL1 via noncanonical oligomerization and breaching of the outer mitochondrial membrane permeability barrier — a function absent in BCLXL and distinct from BAX.","method":"Synthetic membrane models (liposomes), quantitative permeabilization assays, cell-based assays, protein oligomerization analysis","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in defined lipid systems plus cell-based validation, mechanistic dissection with multiple conditions","pmids":["30560933"],"is_preprint":false},{"year":2020,"finding":"Disulfide tethering screen identified that C55 of BFL-1 in its BH3-binding groove can be targeted by small molecules; an N-acetyltryptophan analog (304 Da adduct) covalently targets C55, blocks BH3-binding functionality, and reverses BFL-1-mediated suppression of mitochondrial apoptosis. Structural analysis implicated the conserved leucine-binding pocket with conformational remodeling.","method":"Disulfide tethering screen, X-ray crystallography of covalent complex, mitochondrial apoptosis assay","journal":"Cell chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural determination of covalent complex plus functional mitochondrial assay, multiple orthogonal methods","pmids":["32413285"],"is_preprint":false},{"year":2021,"finding":"CDK9 inhibitors rapidly downregulate both BFL-1 and MCL-1 at the transcriptional level, inducing apoptosis in BH3-mimetic-resistant lymphoma cell lines in vitro and driving tumor regressions in vivo in DLBCL patient-derived xenograft models expressing Bfl-1.","method":"CDK9 inhibitor treatment, western blot, in vitro apoptosis assay, PDX in vivo model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro plus in vivo PDX model with defined mechanism, single lab","pmids":["33259592"],"is_preprint":false},{"year":2022,"finding":"BCL2A1 transcription is regulated by STAT5 downstream of FLT3-ITD signaling; gilteritinib (type I TKI) inhibits BCL2A1 expression through STAT5 inactivation. BCL2A1 promoter contains a BRD4 binding site; BET inhibitor CPI-0610 downregulates BCL2A1 in FLT3-mutated AML cells.","method":"CAGE technology, western blot, overexpression, STAT5 inhibition, BET inhibitor treatment","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CAGE plus functional overexpression, pathway inhibition, single lab","pmids":["35114569"],"is_preprint":false},{"year":2023,"finding":"CARD11 gain-of-function mutations directly increase transcription of BCL2A1 via NF-κB1 pathway in mantle cell lymphoma, leading to venetoclax resistance. MALT1 protease inhibition reduces BCL2A1 expression by blocking CARD11-dependent NF-κB1 transduction.","method":"Single-cell RNA-seq, genomic analysis, functional overexpression, MALT1 inhibitor treatment, in vitro and in vivo models","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — integrative genomics plus functional studies in vitro and in vivo, single lab","pmids":["37562004"],"is_preprint":false},{"year":2024,"finding":"A DNA-encoded chemical library screen identified the first reversible covalent small-molecule ligand for BFL-1 binding through Cys55 (cyano-acrylamide mechanism). Cocrystal structure confirmed Cys55 covalent binding mode in the BFL-1 BH3-binding groove.","method":"DEL screen, biophysical assays, X-ray crystallography of covalent complex, SAR exploration","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of covalent complex plus biochemical validation, single lab but structural rigor","pmids":["38894895"],"is_preprint":false}],"current_model":"BCL2A1/BFL-1 is an NF-κB-regulated anti-apoptotic BCL-2 family protein that localizes predominantly to the outer mitochondrial membrane via its amphipathic C-terminal helix (α9), where it inhibits apoptosis by sequestering pro-apoptotic BH3 proteins (particularly BAX via direct interaction and BIM through the BH3-binding groove) and blocking cytochrome c release; its activity is post-translationally regulated by ubiquitin-mediated proteasomal degradation with TRIM28 as the E3 ligase (antagonized by TRIM17 and modulated by GSK3 phosphorylation), while calpain cleavage converts it from anti- to pro-apoptotic by releasing membrane-active C-terminal helices; BFL-1 is transcriptionally induced by multiple upstream pathways including NF-κB (activated by LMP1, Tax, CARD11, TNF-α, FGF-2, and oxidative stress), MITF in melanoma, WT1 in myeloid cells, Spi-B in plasmacytoid dendritic cells, and EBNA2 via CBF1/Notch signaling, making it a context-dependent survival factor in hematopoietic cells and a resistance determinant against BH3-mimetic therapies; uniquely among BCL-2 family members, BFL-1 possesses a surface-accessible C55 within its BH3-binding groove enabling selective covalent targeting, and under apoptotic lipid conditions in the OMM it can oligomerize and permeabilize the mitochondrial membrane through a pro-death mechanism absent in other anti-apoptotic BCL-2 proteins."},"narrative":{"mechanistic_narrative":"BCL2A1/BFL-1 is an anti-apoptotic BCL-2 family protein that functions as a context-dependent survival factor in hematopoietic and malignant cells, blocking the mitochondrial (intrinsic) apoptotic pathway [PMID:7478596, PMID:8752150, PMID:10753914]. It inhibits cell death by directly engaging pro-apoptotic effectors and BH3-only proteins: it binds the BAX BH3 domain without forming homodimers or heterodimerizing with BCL-2/BCL-xL [PMID:10753914], and its BH3-binding groove captures BIM, the structural basis of which was defined by crystallography revealing distinct binding-site plasticity relative to MCL-1 [PMID:18812174]. Mutagenesis localized anti-apoptotic, oncogene-cooperation, and proliferation-permitting activities to the BH1, BH2, and BH4 domains rather than its own BH3 [PMID:9671389]. BFL-1 is anchored to the outer mitochondrial membrane through its amphipathic C-terminal helix α9, which regulates its anti-apoptotic function [PMID:19759007]. Its protein level is set by ubiquitin-mediated proteasomal degradation that acts as a tumor-suppressive brake — TRIM28 serves as the mitochondrial E3 ligase, antagonized by TRIM17 and modulated by GSK3 phosphorylation — and ubiquitination-resistant mutants accelerate leukemia/lymphoma formation in vivo [PMID:20185581, PMID:30042493]. BFL-1 transcription is induced by a broad array of upstream signals, predominantly through NF-κB (driven by LMP1/CD40, HTLV-1 Tax, TNF-α, CARD11, and MUC1-C), as well as by EBNA2 via CBF1/Notch, the lineage factors WT1, Spi-B, and MITF, and FLT3-ITD/STAT5 signaling [PMID:11039911, PMID:14747545, PMID:16484585, PMID:16873269, PMID:22510878, PMID:22553204, PMID:23447565, PMID:35114569, PMID:37562004]. This inducibility makes BFL-1 a recurrent resistance determinant against BH3-mimetics such as ABT-737/venetoclax, where it sequesters BIM displaced from BCL-2 [PMID:19008458, PMID:20197552, PMID:37562004]. Paradoxically, BFL-1 also harbors latent pro-death activity: calpain cleavage releases membrane-active C-terminal helices that drive cytochrome c release (helix α5 via BAX/BAK, helix α9 through a BAX/BAK-independent membrane-destabilizing mechanism) [PMID:22745672], and under apoptotic OMM lipid conditions full-length BFL-1 can oligomerize and breach the membrane, a function absent in BCL-xL [PMID:30560933]. Uniquely among anti-apoptotic BCL-2 proteins, BFL-1 presents a surface-accessible cysteine (C55) within its BH3-binding groove, enabling selective covalent inhibition by NOXA-derived stapled peptides, designed PUMA variants, and small molecules [PMID:27617850, PMID:29276033, PMID:28594323, PMID:32413285, PMID:38894895].","teleology":[{"year":1995,"claim":"Established BCL2A1 as a distinct anti-apoptotic BCL-2 family member, defining the gene's molecular identity and tissue bias.","evidence":"cDNA cloning, sequence analysis, and Northern blot showing BH1/BH2 domains and bone-marrow-preferential expression","pmids":["7478596"],"confidence":"Medium","gaps":["No functional anti-apoptotic assay in initial report","Domain requirements not yet mapped"]},{"year":1996,"claim":"Demonstrated that BFL-1 has genuine anti-apoptotic and oncogenic activity, moving it from a sequence homolog to a functional survival/transformation factor.","evidence":"Overexpression suppressing p53-induced apoptosis and cooperating with E1A in transformation of primary rodent cells","pmids":["8752150"],"confidence":"Medium","gaps":["Mechanism of apoptosis suppression unresolved","Binding partners not identified"]},{"year":1998,"claim":"Mapped the functional architecture of BFL-1, showing the BH1/BH2/BH4 domains (not its own BH3) drive activity and separating proliferation from anti-apoptotic functions.","evidence":"Systematic site-directed mutagenesis with apoptosis and transformation readouts","pmids":["9671389"],"confidence":"High","gaps":["No structural model accompanied the mutagenesis","Direct partner engagement by each domain not tested"]},{"year":2000,"claim":"Identified BAX as a direct binding partner and confirmed selective heterodimerization, establishing the biochemical mechanism of BFL-1 sequestration.","evidence":"Yeast two-hybrid, reciprocal co-IP, yeast lethality rescue, and molecular modeling of a BCL-xL-like fold","pmids":["10753914"],"confidence":"High","gaps":["Structure of complex not solved","Whether other BH3 proteins are bound not addressed"]},{"year":2000,"claim":"Placed BFL-1 downstream of NF-κB and viral oncoproteins, framing it as an inducible survival node coupling inflammatory/viral signaling to apoptosis resistance.","evidence":"Inducible LMP1 system, TNF-α/NF-κB inhibition, and ectopic-expression rescue in lymphoma and lung cancer cells","pmids":["10864681","11039911"],"confidence":"Medium","gaps":["Promoter elements not yet defined","Relative contribution vs other anti-apoptotic genes unclear"]},{"year":2004,"claim":"Dissected the bfl-1 promoter, identifying a specific NF-κB-like motif essential for transactivation by LMP1, CD40, and p65, mechanistically anchoring its NF-κB regulation.","evidence":"Promoter-reporter deletion/mutation mapping, EMSA, and NF-κB inhibition","pmids":["14747545"],"confidence":"High","gaps":["Other transcription factor inputs not yet characterized"]},{"year":2007,"claim":"Identified BFL-1 as a lineage-specific survival factor and direct transcriptional target across hematopoietic contexts (pre-T cells, neutrophils, plasmacytoid DCs).","evidence":"shRNA/siRNA knockdown, ChIP, and caspase/apoptosis assays in pre-TCR, TNF-α-treated neutrophil, and Spi-B-driven DC systems","pmids":["15728238","17942758","22510878"],"confidence":"High","gaps":["In vivo requirement in these lineages not established by these studies","Concentration-dependent dual TNF-α effects mechanistically complex"]},{"year":2007,"claim":"Revealed that BFL-1 contains an intrinsic mitochondria-targeting tail-anchor that can itself induce caspase-dependent death independent of BAX/BAK, foreshadowing latent pro-apoptotic activity.","evidence":"GFP-fusion localization, mutagenesis of ATAP residues 147-175, and caspase assays in Bax/Bak-deficient cells","pmids":["17666431"],"confidence":"High","gaps":["Physiological trigger for ATAP release not yet known","Relationship to full-length anti-apoptotic function unclear"]},{"year":2008,"claim":"Provided the first crystal structure of BFL-1 (with BIM BH3), defining the structural basis for its BH3-binding multi-specificity.","evidence":"X-ray crystallography of the BFL-1:BIM BH3 complex","pmids":["18812174"],"confidence":"High","gaps":["Apo structure and groove dynamics not yet captured","Druggable features not yet exploited"]},{"year":2009,"claim":"Established that the amphipathic α9 helix anchors endogenous BFL-1 to mitochondria and tunes anti-apoptotic activity, localizing function to the OMM.","evidence":"Subcellular fractionation, confocal imaging, and functional assays in lymphocytes and malignant B cells","pmids":["19759007"],"confidence":"Medium","gaps":["α9 not strictly required for anti-apoptotic activity — secondary localization mechanisms unresolved"]},{"year":2010,"claim":"Defined ubiquitination as a tumor-suppressive regulatory brake on BFL-1, with stabilization accelerating malignancy in vivo.","evidence":"Ubiquitination-resistant mutants in a mouse leukemia/lymphoma model with Lck/IKK/Akt/ERK signaling analysis","pmids":["20185581"],"confidence":"High","gaps":["E3 ligase identity not yet established","Phospho-regulation not defined"]},{"year":2010,"claim":"Mechanistically linked BFL-1 to BH3-mimetic resistance, showing it sequesters BIM displaced from BCL-2 by ABT-737 in lymphoma and the CLL microenvironment.","evidence":"Resistant cell lines, CD154/IL-4 co-culture, BIM co-IP, and shRNA rescue","pmids":["19008458","20197552"],"confidence":"Medium","gaps":["Relative weighting vs MCL-1 context-dependent","Whether covalent targeting could overcome resistance untested here"]},{"year":2012,"claim":"Uncovered a conditional pro-apoptotic conversion of BFL-1, where calpain cleavage liberates membrane-active helices driving cytochrome c release through both BAX/BAK-dependent and -independent routes.","evidence":"In vitro calpain cleavage, isolated-mitochondria permeabilization, domain mutagenesis, and Bax/Bak-deficient controls","pmids":["22745672"],"confidence":"High","gaps":["In vivo relevance of calpain switch not established","Trigger for calpain access to BFL-1 unclear"]},{"year":2013,"claim":"Identified MITF-driven BCL2A1 amplification as a melanoma-specific oncogenic dependency, extending BFL-1 biology beyond hematopoiesis.","evidence":"ChIP, promoter assays, shRNA/overexpression, and xenograft models in melanoma and melanocytes","pmids":["23447565","25486183"],"confidence":"High","gaps":["Why MITF restricts high expression to melanoma not fully resolved"]},{"year":2015,"claim":"Demonstrated an in vivo physiological requirement for BCL2A1 in mature B-cell homeostasis via a BCR/Syk/Btk-driven A1/BIM survival axis.","evidence":"Conditional knockdown mouse model with flow cytometry and Syk/Btk inhibitor epistasis","pmids":["26450454"],"confidence":"High","gaps":["Knockdown (not full knockout) leaves residual function unresolved"]},{"year":2018,"claim":"Identified TRIM28 as the BFL-1 E3 ligase counteracted by TRIM17 and GSK3, completing the post-translational degradation circuit at mitochondria.","evidence":"Reciprocal mitochondrial co-IP, ubiquitination and knockdown assays, GSK3 pharmacology","pmids":["30042493"],"confidence":"High","gaps":["Precise GSK3 phospho-sites and degron not mapped","Stoichiometry of TRIM17/TRIM28 competition unclear"]},{"year":2018,"claim":"Resolved three membrane-level inhibitory mechanisms and a lipid-triggered pro-death function in which BFL-1 oligomerizes to breach the OMM — a property unique among anti-apoptotic BCL-2 proteins.","evidence":"Liposome reconstitution, quantitative permeabilization assays, oligomerization analysis, and cell-based validation","pmids":["30560933"],"confidence":"High","gaps":["Physiological lipid changes that flip the switch not defined in cells","Structural form of the oligomer unknown"]},{"year":2017,"claim":"Solved apo and ligand-bound BFL-1 structures revealing a surface-accessible C55 in the BH3-binding groove and defined covalent and computationally designed BH3 ligands as selective BFL-1 inhibitors.","evidence":"Crystallography of apo and covalent complexes, stapled/designed BH3 peptides validated by MS, FP binding, and mitochondrial/cell apoptosis assays","pmids":["27617850","28026162","29276033","28594323"],"confidence":"High","gaps":["Peptide leads not yet drug-like for in vivo use"]},{"year":2024,"claim":"Advanced selective BFL-1 inhibition from peptides to small molecules, establishing C55-targeting covalent chemistry as a tractable therapeutic strategy.","evidence":"Disulfide tethering and DNA-encoded library screens with cocrystal structures of covalent C55 adducts and mitochondrial apoptosis assays","pmids":["32413285","38894895"],"confidence":"High","gaps":["Cellular potency and selectivity in vivo not yet established","Pharmacokinetics of covalent ligands undefined"]},{"year":2023,"claim":"Extended the NF-κB-driven resistance paradigm to defined oncogenic lesions, showing CARD11 gain-of-function and FLT3-ITD/STAT5 drive BCL2A1-mediated venetoclax/therapy resistance that can be reversed pharmacologically.","evidence":"scRNA-seq, MALT1/MUC1-C/STAT5/BET/CDK9 inhibition with in vitro and PDX models","pmids":["29760958","33259592","35114569","37562004"],"confidence":"Medium","gaps":["Direct vs indirect transcriptional effects of some inhibitors not fully separated","Combination strategies not clinically validated"]},{"year":null,"claim":"How the anti-apoptotic versus pro-death balance of BFL-1 is governed in living cells — the in vivo triggers for calpain cleavage and lipid-induced oligomerization — and whether covalent C55 inhibitors achieve durable efficacy in vivo remain open.","evidence":"","pmids":[],"confidence":"High","gaps":["No in vivo demonstration of the lipid/calpain pro-death switch","Small-molecule BFL-1 inhibitors not yet validated in animal disease models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[3,17,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,3,22]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[19,22,33]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[16,19,25,31]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,3,22,33]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,23,26,36]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,24,37]}],"complexes":[],"partners":["BAX","BIM","NOXA","TRIM28","TRIM17","GSK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16548","full_name":"Bcl-2-related protein A1","aliases":["Bcl-2-like protein 5","Bcl2-L-5","Hemopoietic-specific early response protein","Protein BFL-1","Protein GRS"],"length_aa":175,"mass_kda":20.1,"function":"Retards apoptosis induced by IL-3 deprivation. May function in the response of hemopoietic cells to external signals and in maintaining endothelial survival during infection (By similarity). Can inhibit apoptosis induced by serum starvation in the mammary epithelial cell line HC11 (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q16548/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2A1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2A1","total_profiled":1310},"omim":[{"mim_id":"615559","title":"AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3","url":"https://www.omim.org/entry/615559"},{"mim_id":"601056","title":"BCL2-RELATED PROTEIN A1; BCL2A1","url":"https://www.omim.org/entry/601056"},{"mim_id":"189965","title":"CCAAT/ENHANCER-BINDING PROTEIN, BETA; CEBPB","url":"https://www.omim.org/entry/189965"},{"mim_id":"105590","title":"ALK RECEPTOR TYROSINE KINASE; ALK","url":"https://www.omim.org/entry/105590"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":583.4}],"url":"https://www.proteinatlas.org/search/BCL2A1"},"hgnc":{"alias_symbol":["GRS","BFL1","BCL2L5","ACC-1","ACC-2","ACC2","ACC1"],"prev_symbol":["HBPA1"]},"alphafold":{"accession":"Q16548","domains":[{"cath_id":"1.10.437.10","chopping":"7-174","consensus_level":"high","plddt":87.6186,"start":7,"end":174}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16548","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16548-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16548-F1-predicted_aligned_error_v6.png","plddt_mean":87.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2A1","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2A1"},"sequence":{"accession":"Q16548","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16548.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16548/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16548"}},"corpus_meta":[{"pmid":"20197552","id":"PMC_20197552","title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20197552","citation_count":312,"is_preprint":false},{"pmid":"19008458","id":"PMC_19008458","title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19008458","citation_count":292,"is_preprint":false},{"pmid":"12391199","id":"PMC_12391199","title":"4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12391199","citation_count":285,"is_preprint":false},{"pmid":"22075983","id":"PMC_22075983","title":"BCL2A1: the underdog in the BCL2 family.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22075983","citation_count":255,"is_preprint":false},{"pmid":"23447565","id":"PMC_23447565","title":"BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23447565","citation_count":191,"is_preprint":false},{"pmid":"8895507","id":"PMC_8895507","title":"Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8895507","citation_count":159,"is_preprint":false},{"pmid":"7478596","id":"PMC_7478596","title":"A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7478596","citation_count":133,"is_preprint":false},{"pmid":"17111047","id":"PMC_17111047","title":"Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17111047","citation_count":132,"is_preprint":false},{"pmid":"12771180","id":"PMC_12771180","title":"Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12771180","citation_count":118,"is_preprint":false},{"pmid":"22604450","id":"PMC_22604450","title":"Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM).","date":"2012","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/22604450","citation_count":114,"is_preprint":false},{"pmid":"19700546","id":"PMC_19700546","title":"ACC (1-aminocyclopropane-1-carboxylate) deaminase activity, a widespread trait in Burkholderia species, and its growth-promoting effect on tomato plants.","date":"2009","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19700546","citation_count":108,"is_preprint":false},{"pmid":"15728238","id":"PMC_15728238","title":"The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15728238","citation_count":98,"is_preprint":false},{"pmid":"8752150","id":"PMC_8752150","title":"bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8752150","citation_count":97,"is_preprint":false},{"pmid":"10428914","id":"PMC_10428914","title":"A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia.","date":"1999","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/10428914","citation_count":95,"is_preprint":false},{"pmid":"11039911","id":"PMC_11039911","title":"Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11039911","citation_count":91,"is_preprint":false},{"pmid":"17942758","id":"PMC_17942758","title":"The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17942758","citation_count":80,"is_preprint":false},{"pmid":"18045785","id":"PMC_18045785","title":"GRSDB2 and GRS_UTRdb: databases of quadruplex forming G-rich sequences in pre-mRNAs and mRNAs.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18045785","citation_count":77,"is_preprint":false},{"pmid":"19383158","id":"PMC_19383158","title":"The chemoreceptor genes of the waterflea Daphnia pulex: many Grs but no Ors.","date":"2009","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/19383158","citation_count":77,"is_preprint":false},{"pmid":"23052335","id":"PMC_23052335","title":"Single-copy gene fluorescence in situ hybridization and genome analysis: Acc-2 loci mark evolutionary chromosomal rearrangements in wheat.","date":"2012","source":"Chromosoma","url":"https://pubmed.ncbi.nlm.nih.gov/23052335","citation_count":77,"is_preprint":false},{"pmid":"22875003","id":"PMC_22875003","title":"Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22875003","citation_count":74,"is_preprint":false},{"pmid":"10828397","id":"PMC_10828397","title":"Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei.","date":"2000","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/10828397","citation_count":73,"is_preprint":false},{"pmid":"10864681","id":"PMC_10864681","title":"The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.","date":"2000","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10864681","citation_count":70,"is_preprint":false},{"pmid":"15617521","id":"PMC_15617521","title":"Anaplasma phagocytophilum inhibits human neutrophil apoptosis via upregulation of bfl-1, maintenance of mitochondrial membrane potential and prevention of caspase 3 activation.","date":"2005","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15617521","citation_count":68,"is_preprint":false},{"pmid":"27617850","id":"PMC_27617850","title":"Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.","date":"2016","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27617850","citation_count":65,"is_preprint":false},{"pmid":"8691468","id":"PMC_8691468","title":"Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach.","date":"1996","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8691468","citation_count":65,"is_preprint":false},{"pmid":"15499630","id":"PMC_15499630","title":"High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15499630","citation_count":64,"is_preprint":false},{"pmid":"10753914","id":"PMC_10753914","title":"Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10753914","citation_count":63,"is_preprint":false},{"pmid":"18812174","id":"PMC_18812174","title":"Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18812174","citation_count":63,"is_preprint":false},{"pmid":"9671389","id":"PMC_9671389","title":"Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9671389","citation_count":59,"is_preprint":false},{"pmid":"9264153","id":"PMC_9264153","title":"Behavioral and neuroendocrine responses controlled by the concerted action of central mineralocorticoid (MRS) and glucocorticoid receptors (GRS).","date":"1997","source":"Psychoneuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9264153","citation_count":55,"is_preprint":false},{"pmid":"29760958","id":"PMC_29760958","title":"Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer.","date":"2018","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29760958","citation_count":51,"is_preprint":false},{"pmid":"30042493","id":"PMC_30042493","title":"TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30042493","citation_count":50,"is_preprint":false},{"pmid":"22865454","id":"PMC_22865454","title":"Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22865454","citation_count":50,"is_preprint":false},{"pmid":"17726463","id":"PMC_17726463","title":"Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17726463","citation_count":50,"is_preprint":false},{"pmid":"29584430","id":"PMC_29584430","title":"Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29584430","citation_count":49,"is_preprint":false},{"pmid":"10817695","id":"PMC_10817695","title":"Biochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei.","date":"2000","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/10817695","citation_count":49,"is_preprint":false},{"pmid":"14747545","id":"PMC_14747545","title":"Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14747545","citation_count":48,"is_preprint":false},{"pmid":"16339527","id":"PMC_16339527","title":"Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16339527","citation_count":45,"is_preprint":false},{"pmid":"16484585","id":"PMC_16484585","title":"The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16484585","citation_count":42,"is_preprint":false},{"pmid":"29276033","id":"PMC_29276033","title":"Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor.","date":"2017","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/29276033","citation_count":40,"is_preprint":false},{"pmid":"16048985","id":"PMC_16048985","title":"In vivo transfer of plasmid-encoded ACC-1 AmpC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K. pneumoniae.","date":"2005","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/16048985","citation_count":40,"is_preprint":false},{"pmid":"15592513","id":"PMC_15592513","title":"Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15592513","citation_count":39,"is_preprint":false},{"pmid":"7606363","id":"PMC_7606363","title":"Characterization of a new family of tobacco highly repetitive DNA, GRS, specific for the Nicotiana tomentosiformis genomic component.","date":"1995","source":"Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology","url":"https://pubmed.ncbi.nlm.nih.gov/7606363","citation_count":38,"is_preprint":false},{"pmid":"25486183","id":"PMC_25486183","title":"Role of the pro-survival molecule Bfl-1 in melanoma.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25486183","citation_count":37,"is_preprint":false},{"pmid":"9494579","id":"PMC_9494579","title":"Expression of a novel Bcl-2 related gene, Bfl-1, in various human cancers and cancer cell lines.","date":"1997","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9494579","citation_count":37,"is_preprint":false},{"pmid":"22553204","id":"PMC_22553204","title":"Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22553204","citation_count":36,"is_preprint":false},{"pmid":"28594323","id":"PMC_28594323","title":"Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28594323","citation_count":35,"is_preprint":false},{"pmid":"22617452","id":"PMC_22617452","title":"FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells.","date":"2012","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/22617452","citation_count":34,"is_preprint":false},{"pmid":"28026162","id":"PMC_28026162","title":"hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.","date":"2016","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/28026162","citation_count":34,"is_preprint":false},{"pmid":"23363053","id":"PMC_23363053","title":"Peptide ligands for pro-survival protein Bfl-1 from computationally guided library screening.","date":"2013","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/23363053","citation_count":33,"is_preprint":false},{"pmid":"22510878","id":"PMC_22510878","title":"The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22510878","citation_count":33,"is_preprint":false},{"pmid":"25621074","id":"PMC_25621074","title":"MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2.","date":"2014","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25621074","citation_count":32,"is_preprint":false},{"pmid":"32413285","id":"PMC_32413285","title":"Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering.","date":"2020","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32413285","citation_count":32,"is_preprint":false},{"pmid":"12717423","id":"PMC_12717423","title":"Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12717423","citation_count":32,"is_preprint":false},{"pmid":"25012986","id":"PMC_25012986","title":"Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25012986","citation_count":30,"is_preprint":false},{"pmid":"31971799","id":"PMC_31971799","title":"Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31971799","citation_count":29,"is_preprint":false},{"pmid":"16918505","id":"PMC_16918505","title":"IgE-receptor activation induces survival and Bfl-1 expression in human mast cells but not basophils.","date":"2006","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/16918505","citation_count":29,"is_preprint":false},{"pmid":"11986918","id":"PMC_11986918","title":"Purification and characterization of maltooligosaccharide-forming amylase from Bacillus circulans GRS 313.","date":"2002","source":"Journal of industrial microbiology & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/11986918","citation_count":29,"is_preprint":false},{"pmid":"34034128","id":"PMC_34034128","title":"Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34034128","citation_count":28,"is_preprint":false},{"pmid":"26201458","id":"PMC_26201458","title":"The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis.","date":"2015","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/26201458","citation_count":27,"is_preprint":false},{"pmid":"9050999","id":"PMC_9050999","title":"GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9050999","citation_count":27,"is_preprint":false},{"pmid":"30520678","id":"PMC_30520678","title":"Disruption and Overexpression of the Gene Encoding ACC (1-Aminocyclopropane-1-Carboxylic Acid) Deaminase in Soil-Borne Fungal Pathogen Verticillium dahliae Revealed the Role of ACC as a Potential Regulator of Virulence and Plant Defense.","date":"2019","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/30520678","citation_count":27,"is_preprint":false},{"pmid":"11873633","id":"PMC_11873633","title":"[Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella) isolated from a Tunisian hospital (Sfax 997-2000)].","date":"2002","source":"Pathologie-biologie","url":"https://pubmed.ncbi.nlm.nih.gov/11873633","citation_count":27,"is_preprint":false},{"pmid":"14871250","id":"PMC_14871250","title":"Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/14871250","citation_count":26,"is_preprint":false},{"pmid":"30773399","id":"PMC_30773399","title":"Tertiary Structural Motif Sequence Statistics Enable Facile Prediction and Design of Peptides that Bind Anti-apoptotic Bfl-1 and Mcl-1.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30773399","citation_count":26,"is_preprint":false},{"pmid":"23152563","id":"PMC_23152563","title":"Suppressors of cytokine signaling promote Fas-induced apoptosis through downregulation of NF-κB and mitochondrial Bfl-1 in leukemic T cells.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23152563","citation_count":26,"is_preprint":false},{"pmid":"17666431","id":"PMC_17666431","title":"The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17666431","citation_count":25,"is_preprint":false},{"pmid":"21550593","id":"PMC_21550593","title":"The respective and interaction effects of spinal GRs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat.","date":"2011","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/21550593","citation_count":25,"is_preprint":false},{"pmid":"31411515","id":"PMC_31411515","title":"MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer.","date":"2019","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/31411515","citation_count":24,"is_preprint":false},{"pmid":"33259592","id":"PMC_33259592","title":"Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33259592","citation_count":24,"is_preprint":false},{"pmid":"20185581","id":"PMC_20185581","title":"Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20185581","citation_count":24,"is_preprint":false},{"pmid":"19759007","id":"PMC_19759007","title":"C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19759007","citation_count":23,"is_preprint":false},{"pmid":"428013","id":"PMC_428013","title":"Studies on lung tumours. IV. Correlation between [3H]thymidine labelling of lung and liver cells and tumour formation in GRS/A and C3Hf/A male mice following administration of dimethylnitrosamine.","date":"1979","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/428013","citation_count":23,"is_preprint":false},{"pmid":"16873269","id":"PMC_16873269","title":"Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.","date":"2006","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16873269","citation_count":23,"is_preprint":false},{"pmid":"16982793","id":"PMC_16982793","title":"Genetic environment of acquired bla(ACC-1) beta-lactamase gene in Enterobacteriaceae isolates.","date":"2006","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/16982793","citation_count":23,"is_preprint":false},{"pmid":"37562004","id":"PMC_37562004","title":"CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37562004","citation_count":22,"is_preprint":false},{"pmid":"32618200","id":"PMC_32618200","title":"LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism.","date":"2020","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/32618200","citation_count":22,"is_preprint":false},{"pmid":"35114569","id":"PMC_35114569","title":"Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.","date":"2022","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35114569","citation_count":21,"is_preprint":false},{"pmid":"17402365","id":"PMC_17402365","title":"Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus.","date":"2007","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/17402365","citation_count":21,"is_preprint":false},{"pmid":"26450454","id":"PMC_26450454","title":"Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26450454","citation_count":19,"is_preprint":false},{"pmid":"25066930","id":"PMC_25066930","title":"Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation.","date":"2014","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25066930","citation_count":19,"is_preprint":false},{"pmid":"19857134","id":"PMC_19857134","title":"Molecular epidemiology and genetic environment of acquired bla ACC-1 in Salmonella enterica serotype Livingstone causing a large nosocomial outbreak in Tunisia.","date":"2009","source":"Microbial drug resistance (Larchmont, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19857134","citation_count":19,"is_preprint":false},{"pmid":"22156224","id":"PMC_22156224","title":"High-throughput fluorescence polarization assay for chemical library screening against anti-apoptotic Bcl-2 family member Bfl-1.","date":"2011","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/22156224","citation_count":19,"is_preprint":false},{"pmid":"35260587","id":"PMC_35260587","title":"BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35260587","citation_count":18,"is_preprint":false},{"pmid":"21843371","id":"PMC_21843371","title":"The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21843371","citation_count":17,"is_preprint":false},{"pmid":"32790056","id":"PMC_32790056","title":"Selective Covalent Targeting of Anti-apoptotic BFL-1 by a Sulfonium-Tethered Peptide.","date":"2020","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32790056","citation_count":16,"is_preprint":false},{"pmid":"32946961","id":"PMC_32946961","title":"Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury.","date":"2020","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32946961","citation_count":16,"is_preprint":false},{"pmid":"33163271","id":"PMC_33163271","title":"KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33163271","citation_count":16,"is_preprint":false},{"pmid":"22745672","id":"PMC_22745672","title":"µ-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondria-mediated apoptosis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22745672","citation_count":16,"is_preprint":false},{"pmid":"12396132","id":"PMC_12396132","title":"Immobilization of alpha-amylase from Bacillus circulans GRS 313 on coconut fiber.","date":"2002","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12396132","citation_count":16,"is_preprint":false},{"pmid":"9670830","id":"PMC_9670830","title":"Expression of Bfl-1 in normal and tumor tissues: Bfl-1 overexpression in cancer is attributable to its preferential expression in infiltrating inflammatory cells.","date":"1998","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9670830","citation_count":16,"is_preprint":false},{"pmid":"24867259","id":"PMC_24867259","title":"Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24867259","citation_count":15,"is_preprint":false},{"pmid":"32580291","id":"PMC_32580291","title":"An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32580291","citation_count":15,"is_preprint":false},{"pmid":"38894895","id":"PMC_38894895","title":"Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen.","date":"2024","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38894895","citation_count":15,"is_preprint":false},{"pmid":"24809353","id":"PMC_24809353","title":"Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.","date":"2014","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/24809353","citation_count":15,"is_preprint":false},{"pmid":"22115332","id":"PMC_22115332","title":"Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression.","date":"2011","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22115332","citation_count":15,"is_preprint":false},{"pmid":"35900226","id":"PMC_35900226","title":"Last but not least: BFL-1 as an emerging target for anti-cancer therapies.","date":"2022","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/35900226","citation_count":14,"is_preprint":false},{"pmid":"30560933","id":"PMC_30560933","title":"BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30560933","citation_count":14,"is_preprint":false},{"pmid":"30261890","id":"PMC_30261890","title":"Genetic risk score (GRS) constructed from polymorphisms in the PON1, IL-6, ITGB3, and ALDH2 genes is associated with the risk of coronary artery disease in Pakistani subjects.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/30261890","citation_count":14,"is_preprint":false},{"pmid":"23841872","id":"PMC_23841872","title":"BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas.","date":"2013","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23841872","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48509,"output_tokens":9048,"usd":0.140624,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19094,"output_tokens":5994,"usd":0.12266,"stage2_stop_reason":"end_turn"},"total_usd":0.263284,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"BFL-1 (BCL2A1) was identified as a novel BCL-2 family member with 72% amino acid identity to murine A1, containing conserved BH1 and BH2 domains, and preferentially expressed in bone marrow.\",\n      \"method\": \"cDNA cloning, sequence analysis, Northern blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — initial identification by sequence homology and expression analysis, replicated across multiple subsequent studies\",\n      \"pmids\": [\"7478596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BFL-1 suppresses p53-induced apoptosis and cooperates with E1A oncogene in transformation of primary rodent epithelial cells, demonstrating anti-apoptotic and oncogenic activities.\",\n      \"method\": \"Overexpression in cell lines, apoptosis assay, transformation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assays with defined phenotypic readout, single lab, multiple orthogonal assays\",\n      \"pmids\": [\"8752150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Mutational analysis of BFL-1 showed that BH1, BH2, and BH4 domains are required for anti-apoptotic, oncogene cooperation, and proliferation-facilitating activities, while BH3 mutation does not affect function. C-terminal 24 amino acid deletion partially reduces all activities. Gln residues in the N-terminal/BH4 region are essential for the proliferation-permitting activity.\",\n      \"method\": \"Site-directed mutagenesis, overexpression, apoptosis assays, transformation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis across multiple domains with multiple orthogonal functional readouts in a single study\",\n      \"pmids\": [\"9671389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BFL-1 interacts with BAX (but not BCL-2 or BCL-xL) via the BAX BH3 domain, as shown in yeast two-hybrid and co-immunoprecipitation. BFL-1 does not form homodimers. Overexpression confers resistance to apoptosis from serum deprivation in REF52 cells, and neutralizes BAX lethality in yeast. Molecular modeling suggests BFL-1 has a 7-alpha-helix core structure similar to BCL-xL.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, yeast lethality assay, molecular modeling, overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — yeast two-hybrid plus reciprocal co-IP, functional rescue assay, multiple orthogonal methods in one study\",\n      \"pmids\": [\"10753914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"EBV latent membrane protein LMP1 transcriptionally upregulates bfl-1 mRNA in Burkitt's lymphoma cells, partly through increased mRNA stability. Ectopic BFL-1 expression protects against apoptosis from growth factor deprivation in EBV-positive cells.\",\n      \"method\": \"Inducible LMP1 expression system, Northern blot, ectopic overexpression, apoptosis assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible system with defined pathway, single lab, multiple readouts\",\n      \"pmids\": [\"10864681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-alpha and chemotherapeutic agents upregulate BCL-xL and BFL-1/A1 expression via an NF-κB-dependent pathway in A549 lung cancer cells. Ectopic expression of BFL-1/A1 at physiological levels provides differential protection against TNF-alpha and chemotherapy in NF-κB-deficient cells.\",\n      \"method\": \"NF-κB inhibition, ectopic overexpression, cytotoxicity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic NF-κB inhibition with overexpression rescue, single lab\",\n      \"pmids\": [\"11039911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BCL2A1 encodes two HLA-restricted minor histocompatibility antigens (mHAgs) derived from SNP-encoded peptides, presented by HLA-A*2402 and HLA-B*4403 on hematopoietic lineage cells exclusively, identified by CTL clone lytic patterns and minigene transfection/epitope reconstitution assays.\",\n      \"method\": \"CTL clone lysis assays, minigene transfection, synthetic peptide epitope reconstitution, two-point linkage analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (CTL assays, minigene, peptide reconstitution) in one rigorous study\",\n      \"pmids\": [\"12771180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A novel splice variant, Bfl-1S, contains four BH domains and a KKRK nuclear localization sequence at its C-terminus, which directs nuclear localization (demonstrated by GFP fusion confocal microscopy). Bfl-1S has anti-apoptotic function against Bax and staurosporine, inhibiting cleavage of Bid and caspases 3 and 8.\",\n      \"method\": \"RT-PCR, GFP fusion confocal microscopy, co-expression with Bax, caspase activity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by imaging with functional validation, single lab\",\n      \"pmids\": [\"12717423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LMP1 drives bfl-1 promoter activity via NF-κB-dependent mechanism involving TNFR-associated factor 2 recruitment, primarily through CTAR2 domain. A 95-bp promoter region with a novel NF-κB-like binding motif is essential for transactivation by LMP1, CD40, and NF-κB p65. CD40 activation similarly increases bfl-1 mRNA via NF-κB.\",\n      \"method\": \"Promoter-reporter assays, NF-κB inhibition, EMSA, deletion/mutation analysis of promoter\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter-reporter assays with deletion mapping, EMSA, multiple activating signals tested, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"14747545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Pre-TCR signaling induces BCL2A1 expression to promote pre-T cell survival by inhibiting caspase-3 activation. Knockdown of BCL2A1 compromises survival even in the presence of functional pre-TCR signaling.\",\n      \"method\": \"shRNA knockdown, caspase-3 activity assay, pre-TCR signaling pathway analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown with defined cellular phenotype, pathway placement, single lab\",\n      \"pmids\": [\"15728238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BCL2A1 is upregulated by Anaplasma phagocytophilum infection in neutrophils through transcriptional upregulation (blocked by actinomycin D), maintaining mitochondrial membrane potential and preventing caspase-3 activation to inhibit apoptosis.\",\n      \"method\": \"mRNA quantification, actinomycin D block, mitochondrial membrane potential dyes (Mitotracker/JC-1), caspase-3 activity assay\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods linking BCL2A1 transcription to mitochondrial and caspase outcomes, single lab\",\n      \"pmids\": [\"15617521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCL2A1 is a direct transcriptional target of WT1 (-Ex5/-KTS) isoform: promoter-reporter assays and chromatin immunoprecipitation showed direct WT1 binding and activation of the A1/BFL1 promoter. Constitutive A1 expression induces spontaneous granulocytic differentiation and resistance to apoptosis and chemotherapy in 32D cl3 myeloblasts.\",\n      \"method\": \"cDNA array, RT-PCR, promoter-reporter assay, chromatin immunoprecipitation, constitutive expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP plus promoter-reporter plus functional phenotype, multiple orthogonal methods in one study\",\n      \"pmids\": [\"16484585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EBNA2 upregulates bfl-1 transcription through a CBF1/RBP-Jκ-dependent pathway (a Notch signaling component), requiring a core CBF1-binding site on the bfl-1 promoter, and acting independently of NF-κB. Loss of both EBNA2 and LMP1 together is required to significantly reduce bfl-1 expression.\",\n      \"method\": \"Promoter-reporter assays, CBF1 mutant analysis, EBV protein deletion, luciferase assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis with genetic epistasis, single lab\",\n      \"pmids\": [\"16873269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ALK-positive ALCL cells require BCL2A1 expression for survival and growth; BCL2A1 is a transcriptional target of ALK signaling. Functional RNAi knockdown of BCL2A1 in ALK-positive ALCL cells suppresses transformation and survival.\",\n      \"method\": \"Gene expression profiling, inducible RNAi, ALK inhibitors, functional RNAi screen\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible RNAi with defined phenotypic readouts in multiple cell lines, single lab\",\n      \"pmids\": [\"17111047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TNF-alpha induces BFL-1 expression in neutrophils at low concentrations (≤1 ng/mL) while at high concentrations (≥10 ng/mL) it triggers caspase-dependent Mcl-1 degradation. These opposing effects on two separate anti-apoptotic systems explain TNF-alpha's dual effects on neutrophil apoptosis.\",\n      \"method\": \"Western blot, flow cytometry, caspase inhibition, mRNA analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dose-dependent functional dissection with multiple readouts, single lab\",\n      \"pmids\": [\"17942758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Spi-B transcription factor directly induces BCL2-A1 expression to control survival of plasmacytoid dendritic cells and their progenitors during differentiation from hematopoietic precursors.\",\n      \"method\": \"ChIP, promoter assay, siRNA knockdown, flow cytometry apoptosis assay, differentiation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP confirming direct binding plus knockdown plus functional outcome, multiple orthogonal methods\",\n      \"pmids\": [\"22510878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The amphipathic tail-anchoring peptide (ATAP; residues 147-175) of Bfl-1 targets specifically to mitochondria and induces caspase-dependent apoptosis independent of Bax or Bak. Lysine residues flanking ATAP are required for mitochondrial targeting; charged residues contributing to amphipathic character are critical for pro-apoptotic function.\",\n      \"method\": \"GFP-fusion subcellular localization, mutagenesis, caspase assay, Bax/Bak-deficient cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis coupled with direct mitochondrial localization and functional apoptosis assays, multiple orthogonal methods\",\n      \"pmids\": [\"17666431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of BFL-1 in complex with a BIM BH3 peptide reveals distinct features at the peptide-binding site with local plasticity of hydrophobic interactions compared to MCL-1:BIM, suggesting the structural basis for multi-specificity of BIM binding to anti-apoptotic proteins.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — first crystal structure of BFL-1, rigorous structural determination\",\n      \"pmids\": [\"18812174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"De novo synthesis of BCL2A1 (and BCL-xL) mediates ~1000-fold resistance to ABT-737 in CLL cells cultured on CD154-expressing fibroblasts with IL-4 (mimicking lymph node microenvironment), acting upstream of mitochondrial perturbation. BCL2A1 is responsible for resistance at high ABT-737 concentrations.\",\n      \"method\": \"Co-culture model, western blot, protein synthesis inhibition, flow cytometry apoptosis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with upstream/downstream analysis, single lab, multiple methods\",\n      \"pmids\": [\"19008458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The C-terminal helix α9 of Bfl-1 is amphipathic and required for mitochondrial membrane anchoring; endogenous Bfl-1 is tightly associated with mitochondria by its C-terminus in both healthy and apoptotic lymphocytes and malignant B cells. The amphipathic character of α9 regulates the anti-apoptotic function of Bfl-1, though it is not absolutely required for anti-apoptotic activity.\",\n      \"method\": \"Subcellular fractionation, confocal microscopy, molecular modeling, functional anti-apoptotic assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by fractionation and imaging with functional consequence, single lab\",\n      \"pmids\": [\"19759007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ubiquitination is a critical tumor suppressor mechanism for Bfl-1; ubiquitination-resistant mutants show increased protein stability and greatly accelerated tumor formation in a mouse leukemia/lymphoma model. Tyrosine kinase Lck is upregulated in these tumors and activates IκB kinase, Akt, and ERK signaling.\",\n      \"method\": \"Ubiquitination-resistant mutants, mouse leukemia/lymphoma model, shRNA knockdown, western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo mouse model with ubiquitination-resistant mutants plus Lck knockdown rescue, multiple orthogonal methods\",\n      \"pmids\": [\"20185581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Acquired resistance to ABT-737 in lymphoma cells is mediated by increased BFL-1 and/or MCL-1 proteins, which sequester pro-apoptotic BIM after it is displaced from BCL-2 by ABT-737. MCL-1 and BFL-1 upregulation occurs at the transcript level and is also dynamically induced within hours of ABT-737 treatment.\",\n      \"method\": \"Derived resistant cell lines, western blot, shRNA, BIM co-immunoprecipitation, flavopiridol treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with co-IP and shRNA rescue, single lab\",\n      \"pmids\": [\"20197552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"µ-Calpain cleavage of full-length Bfl-1 releases C-terminal membrane-active α-helices, converting Bfl-1 from anti-apoptotic to pro-apoptotic. Helix α5 of Bfl-1 induces cell death and cytochrome c release through a Bax/Bak-dependent mechanism; helix α9 promotes cytochrome c release through a unique membrane-destabilizing action independent of Bax/Bak.\",\n      \"method\": \"In vitro calpain cleavage, isolated mitochondria permeabilization, Bax/Bak-deficient cells, cytochrome c release assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution with isolated mitochondria, domain mutagenesis, and Bax/Bak genetic controls\",\n      \"pmids\": [\"22745672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HTLV-1 Tax protein induces bfl-1 transcription through the canonical NF-κB pathway, and cooperates with c-Jun or JunD (but not JunB) AP-1 transcription factors via NF-κB and AP-1 binding sites in the bfl-1 promoter. HBZ inhibits c-Jun-induced but increases JunD-induced bfl-1 activation. Both Bfl-1 and Bcl-xL (not Bcl-2) are required for HTLV-1-infected T-cell survival.\",\n      \"method\": \"Promoter-reporter assays, ChIP, siRNA knockdown, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP plus promoter-reporter mutation plus siRNA knockdown with survival readout, multiple orthogonal methods\",\n      \"pmids\": [\"22553204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BCL2A1 is a direct transcriptional target of the melanoma oncogene MITF, which restricts high-level BCL2A1 expression to melanoma. BCL2A1 is recurrently amplified in ~30% of melanomas and is necessary for melanoma growth; BCL2A1 overexpression promotes melanomagenesis in BRAF-immortalized melanocytes.\",\n      \"method\": \"ChIP, promoter assays, shRNA knockdown, overexpression in melanocytes, in vivo xenograft\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP demonstrating direct MITF binding, functional knockdown and overexpression, in vivo model, multiple orthogonal methods\",\n      \"pmids\": [\"23447565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Bfl-1 is mitochondrially resident in both resting and apoptotic melanocytes and is regulated by proteasome and NF-κB pathways. siRNA-mediated knockdown enhances sensitivity to drug treatments; forced Bfl-1 overexpression is protective against chemotherapy-induced apoptosis.\",\n      \"method\": \"Subcellular fractionation, siRNA knockdown, proteasome inhibition, NF-κB inhibition, overexpression, apoptosis assay\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence, multiple perturbations, single lab\",\n      \"pmids\": [\"25486183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Conditional knockdown of BCL2A1/A1 in mice defines a critical role in mature B-cell homeostasis, and identifies the A1/Bim axis as a target of BCR-dependent survival signals mediated by Syk and Btk kinases.\",\n      \"method\": \"Conditional knockdown mouse model (rtTA-driven), flow cytometry, genetic epistasis with Syk/Btk inhibitors\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional in vivo knockdown with genetic pathway epistasis, multiple orthogonal experiments\",\n      \"pmids\": [\"26450454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BFL-1 contains a unique surface-accessible cysteine (C55) within its BH3-binding groove. Stapled BH3 peptides bearing acrylamide warheads derived from NOXA BH3 form irreversible covalent bonds with C55 of BFL-1, selectively inhibiting BFL-1 and reactivating apoptosis. A natural juxtaposition of cysteines at the NOXA BH3/BFL-1 interface enables this selectivity.\",\n      \"method\": \"Covalent stapled peptide synthesis, mass spectrometry, in vitro binding assay, cell-based apoptosis assay\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — structural rationale plus covalent chemistry validated by MS plus cell-based functional assay\",\n      \"pmids\": [\"27617850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Human NOXA binds human BFL-1 potently and covalently via conserved Cys residues, with over 100-fold increased affinity over human MCL-1, suggesting that the selectivity of BH3 interactions differs between mouse and human sequences and that BFL-1 is the primary cellular target of NOXA in humans.\",\n      \"method\": \"Binding affinity measurements, mass spectrometry for covalent interaction, BH3 profiling\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding assays and covalent bond characterization by MS, single lab\",\n      \"pmids\": [\"28026162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of apo BFL-1 at 1.69-Å resolution reveals a surface-accessible C55 within the BH3-binding groove, unique among BCL-2 proteins. Crystal structure of BFL-1 in complex with a covalent stapled NOXA BH3 peptide shows sulfhydryl bond formation and a newly formed hydrophobic cavity with conformational change upon BH3 ligand binding.\",\n      \"method\": \"X-ray crystallography (apo and complex structures)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two crystal structures, rigorous structural determination with functional implications\",\n      \"pmids\": [\"29276033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Computationally designed PUMA BH3 variants bearing epistatic mutations bind BFL-1 in a shifted geometry (revealed by crystal structure) with >150-fold selectivity for BFL-1 over other BCL-2 paralogs, potently trigger mitochondrial outer membrane permeabilization in BFL-1-dependent cells, and an electrophile-modified variant reacts with cysteine near the peptide-binding groove to augment specificity.\",\n      \"method\": \"Computational design, crystal structure, fluorescence polarization binding assay, mitochondrial permeabilization assay, cell-based selectivity assay\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus functional validation with mitochondrial assay and cellular selectivity, multiple orthogonal methods\",\n      \"pmids\": [\"28594323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRIM28 is an E3 ubiquitin ligase for BCL2A1; endogenous TRIM28 and BCL2A1 bind each other at mitochondria and TRIM28 knockdown decreases BCL2A1 ubiquitination. TRIM17 stabilizes BCL2A1 by blocking TRIM28 from binding and ubiquitinating BCL2A1. GSK3 is involved in phosphorylation-mediated inhibition of BCL2A1 degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, subcellular fractionation, western blot\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP at mitochondria, knockdown demonstrating E3 activity, GSK3 pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"30042493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MUC1-C activates the BCL2A1 gene via an NF-κB p65-mediated mechanism in TNBC cells, linking MUC1-C/NF-κB signaling to BCL2A1 induction and EMT. Genetic and pharmacologic targeting of MUC1-C suppresses BCL2A1 expression.\",\n      \"method\": \"shRNA and pharmacologic targeting of MUC1-C, NF-κB p65 ChIP/reporter assays, western blot\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacologic perturbations with NF-κB pathway evidence, single lab\",\n      \"pmids\": [\"29760958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BFL1 inhibits apoptosis through three distinct membrane-level mechanisms (differing from BCLXL). Critically, changes in OMM lipid composition during apoptosis activate a pro-death function of BFL1 via noncanonical oligomerization and breaching of the outer mitochondrial membrane permeability barrier — a function absent in BCLXL and distinct from BAX.\",\n      \"method\": \"Synthetic membrane models (liposomes), quantitative permeabilization assays, cell-based assays, protein oligomerization analysis\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in defined lipid systems plus cell-based validation, mechanistic dissection with multiple conditions\",\n      \"pmids\": [\"30560933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disulfide tethering screen identified that C55 of BFL-1 in its BH3-binding groove can be targeted by small molecules; an N-acetyltryptophan analog (304 Da adduct) covalently targets C55, blocks BH3-binding functionality, and reverses BFL-1-mediated suppression of mitochondrial apoptosis. Structural analysis implicated the conserved leucine-binding pocket with conformational remodeling.\",\n      \"method\": \"Disulfide tethering screen, X-ray crystallography of covalent complex, mitochondrial apoptosis assay\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural determination of covalent complex plus functional mitochondrial assay, multiple orthogonal methods\",\n      \"pmids\": [\"32413285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK9 inhibitors rapidly downregulate both BFL-1 and MCL-1 at the transcriptional level, inducing apoptosis in BH3-mimetic-resistant lymphoma cell lines in vitro and driving tumor regressions in vivo in DLBCL patient-derived xenograft models expressing Bfl-1.\",\n      \"method\": \"CDK9 inhibitor treatment, western blot, in vitro apoptosis assay, PDX in vivo model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro plus in vivo PDX model with defined mechanism, single lab\",\n      \"pmids\": [\"33259592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCL2A1 transcription is regulated by STAT5 downstream of FLT3-ITD signaling; gilteritinib (type I TKI) inhibits BCL2A1 expression through STAT5 inactivation. BCL2A1 promoter contains a BRD4 binding site; BET inhibitor CPI-0610 downregulates BCL2A1 in FLT3-mutated AML cells.\",\n      \"method\": \"CAGE technology, western blot, overexpression, STAT5 inhibition, BET inhibitor treatment\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CAGE plus functional overexpression, pathway inhibition, single lab\",\n      \"pmids\": [\"35114569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CARD11 gain-of-function mutations directly increase transcription of BCL2A1 via NF-κB1 pathway in mantle cell lymphoma, leading to venetoclax resistance. MALT1 protease inhibition reduces BCL2A1 expression by blocking CARD11-dependent NF-κB1 transduction.\",\n      \"method\": \"Single-cell RNA-seq, genomic analysis, functional overexpression, MALT1 inhibitor treatment, in vitro and in vivo models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — integrative genomics plus functional studies in vitro and in vivo, single lab\",\n      \"pmids\": [\"37562004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A DNA-encoded chemical library screen identified the first reversible covalent small-molecule ligand for BFL-1 binding through Cys55 (cyano-acrylamide mechanism). Cocrystal structure confirmed Cys55 covalent binding mode in the BFL-1 BH3-binding groove.\",\n      \"method\": \"DEL screen, biophysical assays, X-ray crystallography of covalent complex, SAR exploration\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of covalent complex plus biochemical validation, single lab but structural rigor\",\n      \"pmids\": [\"38894895\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL2A1/BFL-1 is an NF-κB-regulated anti-apoptotic BCL-2 family protein that localizes predominantly to the outer mitochondrial membrane via its amphipathic C-terminal helix (α9), where it inhibits apoptosis by sequestering pro-apoptotic BH3 proteins (particularly BAX via direct interaction and BIM through the BH3-binding groove) and blocking cytochrome c release; its activity is post-translationally regulated by ubiquitin-mediated proteasomal degradation with TRIM28 as the E3 ligase (antagonized by TRIM17 and modulated by GSK3 phosphorylation), while calpain cleavage converts it from anti- to pro-apoptotic by releasing membrane-active C-terminal helices; BFL-1 is transcriptionally induced by multiple upstream pathways including NF-κB (activated by LMP1, Tax, CARD11, TNF-α, FGF-2, and oxidative stress), MITF in melanoma, WT1 in myeloid cells, Spi-B in plasmacytoid dendritic cells, and EBNA2 via CBF1/Notch signaling, making it a context-dependent survival factor in hematopoietic cells and a resistance determinant against BH3-mimetic therapies; uniquely among BCL-2 family members, BFL-1 possesses a surface-accessible C55 within its BH3-binding groove enabling selective covalent targeting, and under apoptotic lipid conditions in the OMM it can oligomerize and permeabilize the mitochondrial membrane through a pro-death mechanism absent in other anti-apoptotic BCL-2 proteins.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL2A1/BFL-1 is an anti-apoptotic BCL-2 family protein that functions as a context-dependent survival factor in hematopoietic and malignant cells, blocking the mitochondrial (intrinsic) apoptotic pathway [#0, #1, #3]. It inhibits cell death by directly engaging pro-apoptotic effectors and BH3-only proteins: it binds the BAX BH3 domain without forming homodimers or heterodimerizing with BCL-2/BCL-xL [#3], and its BH3-binding groove captures BIM, the structural basis of which was defined by crystallography revealing distinct binding-site plasticity relative to MCL-1 [#17]. Mutagenesis localized anti-apoptotic, oncogene-cooperation, and proliferation-permitting activities to the BH1, BH2, and BH4 domains rather than its own BH3 [#2]. BFL-1 is anchored to the outer mitochondrial membrane through its amphipathic C-terminal helix \\u03b19, which regulates its anti-apoptotic function [#19]. Its protein level is set by ubiquitin-mediated proteasomal degradation that acts as a tumor-suppressive brake \\u2014 TRIM28 serves as the mitochondrial E3 ligase, antagonized by TRIM17 and modulated by GSK3 phosphorylation \\u2014 and ubiquitination-resistant mutants accelerate leukemia/lymphoma formation in vivo [#20, #31]. BFL-1 transcription is induced by a broad array of upstream signals, predominantly through NF-\\u03baB (driven by LMP1/CD40, HTLV-1 Tax, TNF-\\u03b1, CARD11, and MUC1-C), as well as by EBNA2 via CBF1/Notch, the lineage factors WT1, Spi-B, and MITF, and FLT3-ITD/STAT5 signaling [#5, #8, #11, #12, #15, #23, #24, #36, #37]. This inducibility makes BFL-1 a recurrent resistance determinant against BH3-mimetics such as ABT-737/venetoclax, where it sequesters BIM displaced from BCL-2 [#18, #21, #37]. Paradoxically, BFL-1 also harbors latent pro-death activity: calpain cleavage releases membrane-active C-terminal helices that drive cytochrome c release (helix \\u03b15 via BAX/BAK, helix \\u03b19 through a BAX/BAK-independent membrane-destabilizing mechanism) [#22], and under apoptotic OMM lipid conditions full-length BFL-1 can oligomerize and breach the membrane, a function absent in BCL-xL [#33]. Uniquely among anti-apoptotic BCL-2 proteins, BFL-1 presents a surface-accessible cysteine (C55) within its BH3-binding groove, enabling selective covalent inhibition by NOXA-derived stapled peptides, designed PUMA variants, and small molecules [#27, #29, #30, #34, #38].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established BCL2A1 as a distinct anti-apoptotic BCL-2 family member, defining the gene's molecular identity and tissue bias.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, and Northern blot showing BH1/BH2 domains and bone-marrow-preferential expression\",\n      \"pmids\": [\"7478596\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional anti-apoptotic assay in initial report\", \"Domain requirements not yet mapped\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that BFL-1 has genuine anti-apoptotic and oncogenic activity, moving it from a sequence homolog to a functional survival/transformation factor.\",\n      \"evidence\": \"Overexpression suppressing p53-induced apoptosis and cooperating with E1A in transformation of primary rodent cells\",\n      \"pmids\": [\"8752150\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of apoptosis suppression unresolved\", \"Binding partners not identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapped the functional architecture of BFL-1, showing the BH1/BH2/BH4 domains (not its own BH3) drive activity and separating proliferation from anti-apoptotic functions.\",\n      \"evidence\": \"Systematic site-directed mutagenesis with apoptosis and transformation readouts\",\n      \"pmids\": [\"9671389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model accompanied the mutagenesis\", \"Direct partner engagement by each domain not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified BAX as a direct binding partner and confirmed selective heterodimerization, establishing the biochemical mechanism of BFL-1 sequestration.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal co-IP, yeast lethality rescue, and molecular modeling of a BCL-xL-like fold\",\n      \"pmids\": [\"10753914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of complex not solved\", \"Whether other BH3 proteins are bound not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed BFL-1 downstream of NF-\\u03baB and viral oncoproteins, framing it as an inducible survival node coupling inflammatory/viral signaling to apoptosis resistance.\",\n      \"evidence\": \"Inducible LMP1 system, TNF-\\u03b1/NF-\\u03baB inhibition, and ectopic-expression rescue in lymphoma and lung cancer cells\",\n      \"pmids\": [\"10864681\", \"11039911\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter elements not yet defined\", \"Relative contribution vs other anti-apoptotic genes unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissected the bfl-1 promoter, identifying a specific NF-\\u03baB-like motif essential for transactivation by LMP1, CD40, and p65, mechanistically anchoring its NF-\\u03baB regulation.\",\n      \"evidence\": \"Promoter-reporter deletion/mutation mapping, EMSA, and NF-\\u03baB inhibition\",\n      \"pmids\": [\"14747545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcription factor inputs not yet characterized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified BFL-1 as a lineage-specific survival factor and direct transcriptional target across hematopoietic contexts (pre-T cells, neutrophils, plasmacytoid DCs).\",\n      \"evidence\": \"shRNA/siRNA knockdown, ChIP, and caspase/apoptosis assays in pre-TCR, TNF-\\u03b1-treated neutrophil, and Spi-B-driven DC systems\",\n      \"pmids\": [\"15728238\", \"17942758\", \"22510878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement in these lineages not established by these studies\", \"Concentration-dependent dual TNF-\\u03b1 effects mechanistically complex\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed that BFL-1 contains an intrinsic mitochondria-targeting tail-anchor that can itself induce caspase-dependent death independent of BAX/BAK, foreshadowing latent pro-apoptotic activity.\",\n      \"evidence\": \"GFP-fusion localization, mutagenesis of ATAP residues 147-175, and caspase assays in Bax/Bak-deficient cells\",\n      \"pmids\": [\"17666431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger for ATAP release not yet known\", \"Relationship to full-length anti-apoptotic function unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided the first crystal structure of BFL-1 (with BIM BH3), defining the structural basis for its BH3-binding multi-specificity.\",\n      \"evidence\": \"X-ray crystallography of the BFL-1:BIM BH3 complex\",\n      \"pmids\": [\"18812174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apo structure and groove dynamics not yet captured\", \"Druggable features not yet exploited\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established that the amphipathic \\u03b19 helix anchors endogenous BFL-1 to mitochondria and tunes anti-apoptotic activity, localizing function to the OMM.\",\n      \"evidence\": \"Subcellular fractionation, confocal imaging, and functional assays in lymphocytes and malignant B cells\",\n      \"pmids\": [\"19759007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"\\u03b19 not strictly required for anti-apoptotic activity \\u2014 secondary localization mechanisms unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined ubiquitination as a tumor-suppressive regulatory brake on BFL-1, with stabilization accelerating malignancy in vivo.\",\n      \"evidence\": \"Ubiquitination-resistant mutants in a mouse leukemia/lymphoma model with Lck/IKK/Akt/ERK signaling analysis\",\n      \"pmids\": [\"20185581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase identity not yet established\", \"Phospho-regulation not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mechanistically linked BFL-1 to BH3-mimetic resistance, showing it sequesters BIM displaced from BCL-2 by ABT-737 in lymphoma and the CLL microenvironment.\",\n      \"evidence\": \"Resistant cell lines, CD154/IL-4 co-culture, BIM co-IP, and shRNA rescue\",\n      \"pmids\": [\"19008458\", \"20197552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative weighting vs MCL-1 context-dependent\", \"Whether covalent targeting could overcome resistance untested here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Uncovered a conditional pro-apoptotic conversion of BFL-1, where calpain cleavage liberates membrane-active helices driving cytochrome c release through both BAX/BAK-dependent and -independent routes.\",\n      \"evidence\": \"In vitro calpain cleavage, isolated-mitochondria permeabilization, domain mutagenesis, and Bax/Bak-deficient controls\",\n      \"pmids\": [\"22745672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of calpain switch not established\", \"Trigger for calpain access to BFL-1 unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified MITF-driven BCL2A1 amplification as a melanoma-specific oncogenic dependency, extending BFL-1 biology beyond hematopoiesis.\",\n      \"evidence\": \"ChIP, promoter assays, shRNA/overexpression, and xenograft models in melanoma and melanocytes\",\n      \"pmids\": [\"23447565\", \"25486183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why MITF restricts high expression to melanoma not fully resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated an in vivo physiological requirement for BCL2A1 in mature B-cell homeostasis via a BCR/Syk/Btk-driven A1/BIM survival axis.\",\n      \"evidence\": \"Conditional knockdown mouse model with flow cytometry and Syk/Btk inhibitor epistasis\",\n      \"pmids\": [\"26450454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Knockdown (not full knockout) leaves residual function unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified TRIM28 as the BFL-1 E3 ligase counteracted by TRIM17 and GSK3, completing the post-translational degradation circuit at mitochondria.\",\n      \"evidence\": \"Reciprocal mitochondrial co-IP, ubiquitination and knockdown assays, GSK3 pharmacology\",\n      \"pmids\": [\"30042493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise GSK3 phospho-sites and degron not mapped\", \"Stoichiometry of TRIM17/TRIM28 competition unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved three membrane-level inhibitory mechanisms and a lipid-triggered pro-death function in which BFL-1 oligomerizes to breach the OMM \\u2014 a property unique among anti-apoptotic BCL-2 proteins.\",\n      \"evidence\": \"Liposome reconstitution, quantitative permeabilization assays, oligomerization analysis, and cell-based validation\",\n      \"pmids\": [\"30560933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological lipid changes that flip the switch not defined in cells\", \"Structural form of the oligomer unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Solved apo and ligand-bound BFL-1 structures revealing a surface-accessible C55 in the BH3-binding groove and defined covalent and computationally designed BH3 ligands as selective BFL-1 inhibitors.\",\n      \"evidence\": \"Crystallography of apo and covalent complexes, stapled/designed BH3 peptides validated by MS, FP binding, and mitochondrial/cell apoptosis assays\",\n      \"pmids\": [\"27617850\", \"28026162\", \"29276033\", \"28594323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide leads not yet drug-like for in vivo use\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Advanced selective BFL-1 inhibition from peptides to small molecules, establishing C55-targeting covalent chemistry as a tractable therapeutic strategy.\",\n      \"evidence\": \"Disulfide tethering and DNA-encoded library screens with cocrystal structures of covalent C55 adducts and mitochondrial apoptosis assays\",\n      \"pmids\": [\"32413285\", \"38894895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular potency and selectivity in vivo not yet established\", \"Pharmacokinetics of covalent ligands undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the NF-\\u03baB-driven resistance paradigm to defined oncogenic lesions, showing CARD11 gain-of-function and FLT3-ITD/STAT5 drive BCL2A1-mediated venetoclax/therapy resistance that can be reversed pharmacologically.\",\n      \"evidence\": \"scRNA-seq, MALT1/MUC1-C/STAT5/BET/CDK9 inhibition with in vitro and PDX models\",\n      \"pmids\": [\"29760958\", \"33259592\", \"35114569\", \"37562004\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect transcriptional effects of some inhibitors not fully separated\", \"Combination strategies not clinically validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the anti-apoptotic versus pro-death balance of BFL-1 is governed in living cells \\u2014 the in vivo triggers for calpain cleavage and lipid-induced oligomerization \\u2014 and whether covalent C55 inhibitors achieve durable efficacy in vivo remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo demonstration of the lipid/calpain pro-death switch\", \"Small-molecule BFL-1 inhibitors not yet validated in animal disease models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [3, 17, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 3, 22]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [19, 22, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [16, 19, 25, 31]},\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [16, 19, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 3, 22, 33]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 23, 26, 36]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 24, 37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAX\", \"BIM\", \"NOXA\", \"TRIM28\", \"TRIM17\", \"GSK3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}